To investigate the role of the STING pathway in TZ‐dSA3‐12‐mediated antitumor effects, we administered H151, a selective STING inhibitor,[24] to E0771‐HER2‐bearing C57BL/6 mice alongside TZ‐dSA3‐12 (3 mg kg−1) for two weeks (Figure S7a, Supporting Information). The combination of H151 and TZ‐dSA3‐12 significantly attenuated the tumor‐suppressive effects of TZ‐dSA3‐12, as evidenced by accelerated tumor growth and increased tumor weight (Figure S7b–d, Supporting Information), without affecting body weight (Figure S7e, Supporting Information). Here, ERBB2 is linked to neoplasm.